Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up After Kite Gene-Modified Cell Therapy
2020-005843-21Phase 2Active
- Sponsor
- Kite Pharma
- Start
- Sep 2021
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of axicabtagene ciloleucel and brexucabtagene autoleucel in B-cell malignancy, acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), sponsored by Kite Pharma. Primary endpoint: Late-onset targeted adverse events and serious adverse events. Started Sep 2021; status: active.
02
Drugs
axicabtagene ciloleucelbrexucabtagene autoleucel
03
Conditions
B-cell malignancyacute myeloid leukemia (AML)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2020-005843-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005843-21.